The companies are subject to either state, federal or congressional inquiries into their marketing practices for prescription opioids, which are blamed for helping to fuel rising numbers or addicted individuals.
FibroGen, Depomed and Valeant were among the biotech stock movers in premarket trading on Aug. 8.
The FDA requested Endo to remove its opioid pain medication from the market, expressing concern that the "benefits of the drug may no longer outweigh its risks."
A review of data produced by BoardEx reveals that many big and small activist-targeted corporate boards feature young directors in their early-to-mid 30s who work for insurgent fund managers
The company's new CEO tells analysts it continues to believe the novel painkiller Nucynta can be a blockbuster.